This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): long-acting recombinant Factor VIIa, MOD-5014, MOD-5017, MOD5014, MOD5017
In preclinical studies, Factor VIIa-CTP was tested via both intravenous and subcutaneous administrations. We have added both routes of administration (ROAs) to this drug profile to refect the drug's current development in both ROAs.
Factor VIIa-CTP is a longer-acting version of recombinant Factor VIIa that uses Carboxyl Terminal Peptide (CTP) technology. CTP is a short, naturally-occurring amino acid sequence that has the effect of slowing the removal/breakdown of the therapeutic protein to which it is attached, thereby extending the time that the protein is active in the body.
Factor VII is a serine protease involved in the initiation of the coagulation cascade in conjunction with tissue factor (TF). Upon binding of TF, factor VII is activated to factor VIIa by various proteases. Substrates of factor VIIa-TF include factor X and factor IX.
PROLOR and OPKO
In April 2013, OPKO and PROLOR announced that the companies signed a definitive merger agreement under which OPKO will acquire PROLOR in an all-stock transaction. Under the terms of the agreement holders of PROLOR common stock will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. In August 2013, OPKO Health and PROLOR Biotech jointly announced the completion of the acquisition of PROLOR by OPKO.
Factor VIIa-CTP News
Additional information available to subscribers only: